MAPT and Alzheimer disease: These pro-inflammatory MGEVs have been shown to contribute to numerous neurological conditions such as the worsening of stroke outcomes in aging populations [161], release amyloid-β and tau proteins into the extracellular space, and activate resting microglia and astrocytes to accelerate the exacerbation of inflammation in AD [63].